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Background: Pepsinogen C (PGC) and mucin1 (MUC1) are important physiologically functional gastric proteins; Mucin2
(MUC2) is an “ectopic” functional protein in intestinal metaplasia of gastric mucosa. We analyzed the co-expression of
the above-mentioned three proteins in dynamic gastric diseases {superficial gastritis (SG)-atrophic gastritis (AG)–gastric
cancer (GC)} as well as different histological types of gastric cancer in order to find molecular phenotypes of gastric
cancer and precancerous disease and further explore the potential co-function of PGC, MUC1 and MUC2 in the
occurrence and development of gastric cancer.
Methods: The SG-AG-GC sequence was 57-57-70 cases in this case–control study, respectively. Different histological
types of GC were 28 cases of highly and moderately differentiated aden ocarcinoma (HMDA)、30 of poorly
differentiated adenocarcinoma (PDA) and 12 of mucinous adenocarcinoma (MA) or signet ring cell carcinoma (SRCC).
PGC, MUC1 and MUC2 expression in situ were detected in all 184 cases using immunohistochemistry.
Results: Both PGC and MUC1 had a significantly decreased expression in GC than in SG and AG (P < 0.0001 and P < 0.01,
respectively); While MUC2 had a significant increased expression in AG than in SG and GC (P < 0.0001). Seven
phenotypes of PGC, MUC1 and MUC2 co-expression were found in which PGC+/MUC1+/MUC2- phenotype took 94.7%
(54/57) in SG group; PGC+/MUC1+/MUC2+ and PGC-/MUC1+/MUC2+ phenotype took 43.9% (25/57) and 52.6% (30/57)
in AG; the phenotypes in GC group appeared variable; extraordinarily, PGC-/MUC1-/MUC2+ phenotype took 100% (6/6)
in MA or SRCC group and had a statistical significance compared with others (P < 0.05).
Conclusions: Phenotypes of PGC, MUC1 and MUC2 co-expression in dynamic gastric diseases are variable. In SG group
it always showed PGC+/MUC1+/MUC2- phenotype and AG group showed two phenotypes (PGC+/MUC1+/MUC2+ and
PGC-/MUC1+/MUC2+); the phenotypes in GC group appeared variable but the phenotype of PGC-/MUC1-/MUC2+ may
be a predictive biomarker for diagnosing MA or SRCC, or distinguishing histological MA or SRCC from tubular
adenocarcinoma accompanied by mucinous secretion or signet ring cell scattered distribution.
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Functional proteinsBackground
Normal function of stomach needs two kinds of mate-
rials which mainly exist in normal gastric juice. They are
protein components and small molecular materials par-
ticipating in regulation. Among them, only pepsinogen* Correspondence: yyuan@mail.cmu.edu.cn
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reproduction in any medium, provided the orand mucin belong to protein components in the gastric
juice which are both important physiologically functional
gastric proteins. Pepsinogens were divided into pepsin-
ogen A (PGA) and pepsinogen C (PGC), and the latter is
a precursor of human pepsin C which is a digestive en-
zyme [1]. The appearance of PGC is a signal of gradually
maturing of digestive function [2]. 1% of human PGC
from the stomach was secreted into peripheral blood
and the ratio of PGA and PGC detected in the serum
was a biomarker for atrophic gastritis (AG) or gastric
cancer (GC) [3-5]. Mucin (MUC) is a kind of glycopro-
tein family secreted by mucosal epithelium possessingThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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thelial lumens, and 20 kinds of mucins had been identified
from MUC1 to MUC21 until now [6]. MUC1 is a highly
polymorphic membrane-associated mucin containing core
peptide chain and glycoprotein side chain. MUC1 pos-
sesses a protective capacity which participates in compos-
ing the barrier of “mucus-bicarbonate” , and also functions
in a cell signaling capacity [7,8]. Its overexpression or aber-
rant intracellular localization is found in cancerous cells
and is associated with carcinomas [9-12].
Except the above-mentioned physiologically functional
gastric proteins, an “ectopic” functional protein, MUC2
could be expressed when the gastric mucosa occurred
intestinal metaplasia. MUC2 is also a highly polymorphic
mucin containing core peptide chain and glycoprotein
side chain [13,14]. In the normal physiological circum-
stances, the MUC2 protein expresses in the intestinal
mucosa and is absent in the normal gastric mucosa.
However, MUC2 could be “ectopic” expressed at gastric
mucosa under pathogenic effect of external factors.
Whether it participates in the response of the host to
these external pathogenic factors such as the inflamma-
tion [15] or H. pylori [16,17] remains controversial.
As physiologically functional gastric proteins and “ec-
topic” expressed protein, the association of PGC, MUC1
and MUC2 solely and gastric diseases had been reported
in the past [18-22]. Our team had also demonstrated in
previous study that PGC expression had a close relation-
ship with the degree of malignancy of gastric mucosa
[23], and we also found MUC1 protein had a significant
underexpression in GC compared with non-cancer sub-
jects [24]. Additionally, MUC2 expression had a close re-
lationship with atrophic gastritis [25]. However, analysis of
these proteins in a same group of cases representing dif-
ferent stages of cancer progression had never been
reported until now, which may provided some new insight
in the possible function of these proteins, and also in
the possible molecular phenotypes of different gastric
diseases.
In this case–control study, we investigated the co-
expression of PGC, MUC1 and MUC2 in situ in the
same group of cases in the SG-AG-GC sequence, as well
as in different histological types of GC in order to find
molecular phenotypes of gastric cancer and precancer-
ous disease and further explore the potential co-function
of PGC, MUC1 and MUC2 in the occurrence and devel-
opment of gastric cancer.
Methods
Patients
This research project was approved by the Ethical Com-
mittee of the China Medical University, and all the gas-
tric tissue specimens of 184 patients were collected from
patients with letters of consent and questionnaire ofmedical history who participated in a health check pro-
gram by gastroscopy for gastric cancer screening or in
hospitals located in Zhuanghe and Shenyang of Liaoning
Province in China between 2002 and 2005. Patients with
a history of other malignant neoplasms or other gastric
benign diseases including gastric erosion, peptic ulcer
diseases, gastric polyp, and adenomas were excluded.
The biopsy specimens from the gastroscopies were
paraffin-embedded and stained by hematoxylin and
eosin (HE) staining method; the eligibility criterion for
all the cases is histological diagnosis. The biopsy speci-
mens were collected from 70 GC patients with an aver-
age age of 59.13 ± 10.50 years ranging from 34 to 80
years old. 57 patients with superficial gastritis (SG) and
57 patients with atrophic gastritis (AG) had a similar
average age of 57.18 ± 11.74 and 57.88 ± 10.62 years re-
spectively, ranging from 34 to 79 years old. The GC and
SG, AG groups had no statistical difference in terms of
gender and age composition (P = 0.812 and P = 0.593,
respectively, Table 1). Furthermore, we classified sam-
ples of 70 GC patients according to WHO classifica-
tion (28 HMDA, 30 PDA and 12 MA or SRCC). The
HMDA, PDA and MA or SRCC subgroups showed no stat-
istical difference in gender and age composition (P = 0.310
and P = 0.141, respectively, Table 1).
Immunohistochemical staining for detection of PGC,
MUC1 and MUC2 protein expression in situ
Immunohistochemical analysis was performed in 5-μm-thick
sections from sequentially sliced samples of formalin-fixed
and paraffin-embedded specimens according to the
method described by Byrd [24,26] with slight modification.
Briefly, tissue sections were deparaffinized and rehydrated.
Endogenous peroxidase was blocked using 3% hydrogen
peroxide in methanol for 10 min and then the sections
were washed with phosphate buffered saline (PBS), pH 7.4.
The sections were incubated with non-immunized horse
serum for 20 min at room temperature and washed before
being incubated with a specific antibody overnight at 4°C.
Then the sections were washed and incubated with
biotinylated secondary antibodies (goat anti-mouse anti-
body, Maixin Inc., Fujian, China) and streptavidin-biotin
peroxidase. After three washes with PBS, the sections were
visualized with 3,3’- diaminobenzidine tetra-hydrochloride
and counterstained with haematoxylin. Primary antibodies
were replaced with PBS buffer as a negative control. The
specific mouse anti-human antibodies were purchased
from Neomarkers Inc. Fremont, USA (Human Milk Fat
Global-1, HMFG-1, against MUC1, 1:200 dilutions) [27,28]
and Maixin Inc. Funjian, China (against MUC2, clone No.
M53, 1:100 dilutions). And mouse anti-human antibody
against PGC (clone No. 2D5, 1:500 dilutions) was
presented by Clinical Laboratory Institute of Japanese,
kindly. Immunohistochemical results were judged by
Table 1 The basic messages of the objects
Variability SG AG GC GC analyzed for PGC, MUC1 and MUC2 (n = 70)
HMDA PDA MA or SRCC
n = 57 n = 57 n = 70 n = 28 n = 30 n = 12
Sex
Male 36 38 48 20 22 6
Female 21 19 22 8 8 6
P = 0.812 P = 0.310
Age
Average 57.88 ± 10.62 57.18 ± 11.74 59.13 ± 10.50 61.54 ± 9.62 58.77 ± 11.05 54.42 ± 10.17
Range 42-79 34-79 34-80 42-80 35-80 34-71
P = 0.593 P = 0.141
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calculated using two indices of proportion (Pί) and in-
tensity (ί). The proportion (Pί) was estimated after tak-
ing into account the percentage of positive cells. The
intensity (ί) was judged as 0 (no staining), 1+ (light
brown staining), 2+ (brown staining), or 3+ (heavy
brown staining). The HSCORE was derived by sum-
ming the proportion of cells staining intensity multi-
plied by the intensity of staining.
HSCORE ¼ ∑Pί ί
Where ί = 0, 1, 2, 3 and Pί varies from 0.0 to 1.0, the
HSCOREs ranged from a minimum of zero in cases with
no staining to a maximum of 3.0 in cases in which all
the cells were stained with maximal intensity. We judged
HSCORE > 0.0 as positive while HSCORE = 0.0 as nega-
tive. The HSCORE was determined by two independent
observers.
Statistics
Non parametric test and Fisher’s exact probabilities were
used to determinate the difference of PGC, MUC1,
MUC2 expression in the SG-AG-GC sequence and in
different histological types of GC. χ2 test and Fisher’s
exact probabilities were used to determinate the differ-
ence of the co-expression of the three proteins. The
rank-sum test and Spearman’s rank correlation analysis
were used to analyze the correlations in different groups.
All statistical analysis was performed using SPSS (16.0)
statistical software program (SPSS, Chicago, USA). All
the statistical test was two-side probability test and
P<0.05 was considered as statistically significant.
Results
The expression of PGC, MUC1, MUC2 in GC and
precancerous diseases groups
PGC expression was found in the cytoplasm of gastric
mucosal cells (Figure 1A). MUC1 expression was foundin the cytoplasm and/or membrane of gastric mucosal
cells (Figure 1E). MUC2 protein was colored in the cyto-
plasm of goblet cells (Figure 1J).
The expression frequency of the three proteins in differ-
ent gastric disease groups was examined by immunohisto-
chemical analysis. PGC and MUC1 proteins expression in
the GC group was significantly lower than that in the SG
and AG groups (P < 0.05). MUC2 protein expression in
the GC group was significantly lower than that in the AG
group (P < 0.001), but the expression of SG group was
lower than that in GC group (P < 0.001). The correlation
of PGC, MUC1 and MUC2 protein expression with SG-
AG-GC sequence was analyzed respectively. We found
there were correlations between these three proteins and
the disease sequence (P < 0.01); PGC and MUC1 showed
negative correlations with the SG-AG-GC sequence
(correlation coefficients were r = −0.770, r = −0.210, re-
spectively; P < 0.001, P = 0.004, respectively ). MUC2 indi-
cated positive correlation with the SG-AG-GC sequence
(correlation coefficient was r = 0.260, P < 0.001). Further-
more, according to WHO histological classification, the
GC group was divided into high and moderated adenocar-
cinoma (HMDA), poorly differentiated adenocarcinoma
(PDA), mucinous adenocarcinoma or signet ring cell car-
cinoma group (MA or SRCC) groups. We found that
MUC1 protein in MA or SRCC group was significantly
lower than that in the HMDA and PDA groups (P < 0.001,
Table 2), and MUC2 in MA or SRCC group was signifi-
cantly higher than that in the PDA groups (P = 0.013,
Table 2), but PGC protein had no significant difference in
the GC group.
The co-expression phenotype of PGC, MUC1, MUC2 in GC
and precancerous disease groups
The co-expression characteristics of PGC, MUC1, MUC2
proteins were analyzed. We found the phenotype of
PGC+/MUC1+/MUC2- accounted for 94.7% (54/57) in
SG group; PGC+/MUC1+/MUC2+ and PGC-/MUC1+
/MUC2+ phenotype accounted for 43.9% (25/57) and
Figure 1 The expression of PGC, MUC1, MUC2 proteins in different gastric mucosa tissues (× 200). A. strong positive expression of PGC in
the gastric mucosa of superficial gastritis (SG) group; B. positive expression of PGC in atrophic gastritis (AG) group, a few negative expression;
C. negative expression of PGC in moderately differentiated adenocarcinoma (MDA) group; D. negative expression of PGC in signet ring cell
carcinoma (SRCC) group. E. strong positive expression of MUC1 in SG group; F. positive expression of MUC1 in AG group; G. positive expression
of MUC1 in poorly differentiated adenocarcinoma (PDA) group; H. negative expression of MUC1 in SRCC group; I. negative expression of MUC2 in
SG group; J. strong positive expression of MUC2 in AG group; K. positive expression of MUC2 in PDA group; L. strong positive expression of
MUC2 in mucinous adenocarcinoma group. The arrow all means the cells of pathological changes.
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in GC group appeared variable, among them, all cases
were PGC- phenotype, in which most were individuals
with phenotype of PGC-/MUC1+/ MUC2+ or PGC-
/MUC1+/MUC2- (33 or 26 cases, accounted for 47.1%
and 37.1% respectively, as shown in Figure 2 A-C or D-F).
Furthermore, the GC cases were classified according to
histological types, we found that 100% (6/6) in the MA or
SRCC group were the phenotype of PGC-/MUC1-/MUC2+
(Figure 2 G-I), other phenotypes group in the MA or SRCC
group were significantly lower compared with that of PGC-
/MUC1-/MUC2+ phenotype group (P < 0.05, Table 3).
The Spearman correlation analysis showed that every
two of PGC, MUC1 and MUC2 had correlation (P < 0.05).
There was a positive correlation between PGC and MUC1
(P = 0.006, r = 0.200), as well as MUC1 and MUC2
(P = 0.177, r = 0.016), while PGC and MUC2 had a
negative correlation but the correlation coefficient was
the largest (P < 0.001, r = −0.313).
Discussion
Pepsinogen C (PGC) and mucin1 (MUC1) are important
physiologically functional gastric proteins; Mucin2 (MUC2)is an “ectopic” functional protein in intestinal metaplasia of
gastric mucosa. We analyzed the co-expression of the these
three proteins in a dynamic gastric disease sequence as well
as different histological types of gastric cancer in order to
explore the co-expression-based molecular phenotypes of
gastric cancer as well as its precancerous disease and cor-
relation between the co-expression pattern and different
gastric diseases.
As we know, PGC, MUC1, MUC2, the three proteins
had solely important diagnostic role for the gastric dis-
ease. But the co-expression as well as their molecular
phenotype had not been reported until now, while in
distinction between different gastric diseases. In fact, the
co-expression of combined proteins suggesting molecu-
lar phenotype like MUC2 and CD10 had been reported
previously. Wakatsuki, K et al. and Hasuo, T et al. di-
vided GC into the gastric phenotype (G-type) and intes-
tinal phenotype (I-type) according to MUC5AC, MUC6,
MUC2, and CD10 [30,31], while other scholars divided
G-type and I-type according to MUC2 with other pro-
teins [20,32]. But the significance of these studies was all
based on the consideration that different phenotypes
had different patterns progressing to GC. We aimed to
Table 2 Frequency of PGC, MUC1 and MUC2 protein
expression in gastric diseases
Staining
score
SG AG GC GC(n = 70)
HMDA PDA MA or
SRCC
n = 57 n = 57 n = 70 n = 28 n = 30 n = 12
PGC
2.0-3.0 19(33.3) 2(3.5) 0(0.0) 0(0.0) 0(0.0) 0(0.0)
1.0-1.9 29(50.9) 14(24.6) 0(0.0) 0(0.0) 0(0.0) 0(0.0)
0.1-0.9 9(15.8) 13(22.8) 0(0.0) 0(0.0) 0(0.0) 0(0.0)
0 0(0.0) 28(49.1) 70(100.0) 28(100.0) 30(100.0) 12(100.0)
P1 <0.0001 <0.0001 -
P2 1.000 1.000 -
MUC1
2.0-3.0 24(42.1) 29(50.9) 21(30.4) 12(42.9) 9(31.0) 0(0.0)
1.0-1.9 19(33.3) 19(33.3) 15(21.7) 8(28.6) 6(20.7) 1(8.3)
0.1-0.9 13(22.8) 9(15.8) 23(33.3) 7(25.0) 12(41.4) 4(33.0)
0 1(1.8) 0(0.0) 10(14.5) 1(3.6) 2(6.9) 7(58.3)
P3 0.012 0.0003 -
P4 <0.0001 0.0004 -
MUC2
2.0-3.0 2(3.5) 46(80.7) 12(17.1) 6(21.4) 2(6.7) 4(33.3)
1.0-1.9 0(0.0) 6(10.5) 8(11.4) 3(10.7) 2(6.7) 3(25.0)
0.1-0.9 0(0.0) 3(5.3) 19(27.1) 9(32.1) 8(26.7) 2(16.7)
0 55(96.5) 2(3.5) 31(44.3) 10(35.7) 18(60.0) 3(25.0)
P5 <0.0001 <0.0001 -
P6 0.273 0.013 -
P7 <0.0001 <0.0001 -
P8 <0.0001 <0.0001 -
P9 <0.0001 0.001 -
Note: Statistical analysis used nonparametric tests and Fisher’s exact tests. P1,
P3, P5 means the significance compared with GC group, respectively. P2, P4, P6
means the significance compared with MA or SRCC group, respectively. P7
means the significance compared with HMDA group; P8 means the
significance compared with PDA group; P9 means the significance compared
with MA or SRCC group.
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which might also give a clue for the understanding of
the progression of gastric diseases.
There were seven types of the co-expression for the
studied three proteins in this study. In SG group it al-
ways showed the phenotype of PGC+/MUC1+/MUC2-
which means PGC and MUC1 were both positive and
MUC2 was negative. We also analyzed the correlations
between the three proteins and the SG-AG-GC sequence
and found that PGC and MUC1 both had negative cor-
relation and only MUC2 had positive correlation with
the disease sequence, which means PGC and MUC1 had
similar distribution tendency while PGC had a larger
correlation coefficient than MUC1 (r = −0.770 andr = −0.210, respectively). In AG group the co-expression
of these three proteins showed two phenotypes (PGC+
/MUC1+/MUC2+ and PGC-/MUC1+/MUC2+) and
the main difference between them was whether PGC
protein was expressed. PGC is a signal of gradually
maturing of digestive function, a differentiation prod-
uct of the digestive enzyme pepsin C, and it was
reported that PGC gradually decreased in the SG–AG-
GC sequence [23]. In our study, PGC was nearly 50%
positive and 50% negative in the AG group. In the dy-
namic change of SG to AG, part of samples appeared
PGC negative while part of samples remained positive.
Among the 50% positive samples, there still were 22.8% of
the cases (13/57, Table 2) which were weak positive
(scored 0.1-0.9). Why part of samples appeared negative
while some still remained positive? There may be two hy-
potheses to explain: first, it may be associated with the de-
gree of glandular atrophy; second, the genetic variability
of human PGC between individuals may contribute to the
different expression of PGC in AG group. Although the
latter was just a hypothesis, other protein like hypoxic
marker carbonic anhydrase (CA) IX had been reported
that genetic methylation status was contribute to the dif-
ferent expression of CA IX in GC group [33]. These hy-
potheses need to be investigated in the future. In GC
group the co-expression of these three proteins appeared
variable, but we found an interesting phenomenon. When
analyzing different histological GC groups, we found the
phenotype of PGC-/MUC1-/MUC2+ all distributed in the
group of mucinous adenocarcinoma or signet ring cell
carcinoma (MA or SRCC, 100%, 6/6). In the clinical
pathological diagnosis, the histological mucinous adeno-
carcinoma and signet ring cell carcinoma were always
hard to distinguish with tubular adenocarcinoma accom-
panied by mucinous secretion or signet ring cell scattered
distribution. In our study, the phenotype of PGC-
/MUC1-/MUC2+ all distributed in the group of MA or
SRCC rather than other groups, which suggested that
the histological worse differentiation MA or SRCC lost
PGC and MUC1 which are biomarkers of mature differen-
tiation. We found MUC1 positive in tubular adenocarcin-
oma. Even though it accompanied mucinous secretion or
signet ring cell scattered distribution, it suggested a better
differentiation so that biomarkers of mature differentiation
like MUC1 and PGC could appear. The phenotype of
PGC-/MUC1-/MUC2+ may be a predictive biomarker for
diagnosing MA or SRCC or distinguishing from tubular
adenocarcinoma accompanied by mucinous secretion or
signet ring cell scattered distribution. Choi and his col-
leagues found mucinous adenocarcinoma always showed
MUC1- and MUC2+ in a study of 133 MA cases [34],
which was consistent with the result of our study. Could
MUC2 solely identify mucinous adenocarcinoma? Prob-
ably no because it was not specific since part of the
Figure 2 The phenotype of PGC/MUC1/MUC2 co-expression in the same pathological changes (× 200). A. The negative expression of PGC
in moderately differentiated adenocarcinoma (MDA) group. B. The positive expression of MUC1 in MDA group. C. The positive expression of
MUC2 in MDA group. D. The negative expression of PGC in poorly differentiated adenocarcinoma (PDA) group. E. The positive expression of
MUC1 in PDA group. F. The negative expression of MUC2 in PDA group. G. The negative expression of PGC in signet ring cell carcinoma (SRCC)
group. H. The negative expression of MUC1 in SRCC group. I. The positive expression of MUC2 in SRCC group. Every three figures in a horizontal
composition were all from the same individual. The arrow all means the cells of pathological changes.
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oma. After adding MUC1 which was a biomarker of ma-
ture differentiation to limit, the identification of MA or
SRCC turned out to be more sensitive.
It is fully aware that our study had some limitations.
First, only gastroscopic biopsy specimens were adopted
and limited clinical data (only age and gender) were
available. Second, the sample of the cases was relatively
small especially GC group and its subgroup analysis. Fu-
ture larger sample study was required to validate our re-
sult. Third, precancerous diseases only included AGTable 3 Different phenotype of the concordance of PGC, MUC
Factors n Different gastric diseases
PGC MUC1 MUC2 SG(n = 57) AG(n = 57) GC(n = 70
- - - 5 - - 5 (100.0)
- - + 6 - - 6 (100.0)
- + - 27 - 1 (3.7) 26 (96.3)
- + + 63 - 30 (47.6) 33 (52.4)
+ - - 1 1 (100.0) - -
+ - + 0 - - -
+ + - 55 54 (98.2) 1 (1.8)
+ + + 27 2 (7.4) 25 (92.6)
Note:*P value meant other group compared with PGC-/MUC1-/MUC2+ phenotype ggroup while other types of precancerous diseases such as
adenomas were not assessed because the sample size of
other precancerous diseases like adenomas was too small
to be a group. Fourth, the current study only discussed
two mucins (i.e. MUC1 and MUC2) and one pepsinogen
PGC without inclusion of other mucins like MUC4
which has been reported increased expression in differ-
ent types of gastric cancer like adenocarcinoma and
SRCC [35] or other gastric functional proteins like pep-
sinogen A [36] and trefoil factors family [37-40]. Further
investigation including stomach-related proteins could1 and MUC2 protein expression in gastric diseases
Different histological type of GC
) HMDA(n = 28) PDA(n = 30) MA or SRCC(n = 12) P*
1 (20.0) 3 (60.0) 1 (20.0) 0.015
- - 6 (100.0) -
9 (34.6) 15 (57.7) 2 (7.7) <0.0001
18 (54.8) 12 (38.7) 3 (6.5) <0.0001
- - - -
- - - -
- - - -
- - - -
roup and used Fisher’s exact probability.
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gastric diseases.
Conclusions
In conclusion, we investigated the co-expression of
PGC, MUC1 and MUC2 in situ of the SG-AG-GC se-
quence, as well as in different histological types of GC.
We found that SG showed PGC+/MUC1+/MUC2-
phenotype and AG showed PGC+/MUC1+/MUC2+ and
PGC-/MUC1+/MUC2+ phenotypes. The phenotype of
PGC-/MUC1-/MUC2+ may be a predictive biomarker
for diagnosing MA or SRCC, or distinguishing histological
MA or SRCC from tubular adenocarcinoma accompanied
by mucinous secretion or signet ring cell scattered distri-
bution. The association between co-function of PGC,
MUC1 and MUC2 and the occurrence and development
of gastric cancer and precancerous disease needs to be
clarified in the future.
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